1. Clinical & Scientific Overview
Montelukast + Levocetirizine Tablets IP (TIP-MED-000517, Reference Code [NLEM-31]) is classified under
Respiratory & Allergy as a LTRA + Second-Generation H1-Antihistamine Allergic Rhinitis FDC.
Within the Indian regulatory and compendial framework, it is governed under Schedule H (Prescription Only — Drugs Rules, 1945).
Montair-LC (Cipla), Montek-LC (Sun Pharma), Telekast-L (Lupin)
Film-Coated Tablets: 10 mg + 5 mg; Paediatric Kid Tablets: 4 mg + 2.5 mg
3. Mechanism of Action & Pharmacodynamics
Complementary dual/multi-mechanism formulation (LTRA + Second-Generation H1-Antihistamine Allergic Rhinitis FDC) providing synergistic therapeutic action.
4. Therapeutic Indications & Evidence-Supported Uses
- Approved clinical management within Respiratory & Allergy per NLEM 2022 / IP 2022 and national treatment guidelines.
🇮🇳 Jurisdiction & Indication Note: Indications and schedules reflect Indian compendial and regulatory records (CDSCO / Indian Pharmacopoeia & NFI / NLEM 2022). Where international reference labels (US FDA DailyMed / NCBI StatPearls) are cited for pharmacokinetic or mechanistic parameters, international approvals do not automatically imply CDSCO approval in India.
5. Educational Dosage Context, Formulations & Administration
Educational Dosing & Regimen Summary: Educational Summary: Administer approved fixed-dose strength (Film-Coated Tablets: 10 mg + 5 mg; Paediatric Kid Tablets: 4 mg + 2.5 mg) according to indication, organ function, and individualised titration.
Administration & Meal Timing: Administer as directed on the approved prescription label.
6. Pharmacokinetics, Metabolism & Renal/Hepatic Adjustment
Component active ingredients follow their established absorption, distribution, hepatic metabolism, and renal elimination profiles.
Hepatic CYP450 / Phase II conjugation depending on constituent active ingredients.
Avoid or adjust fixed-dose combination if eGFR/CrCl falls below threshold for any constituent.
Use with caution or avoid in moderate-to-severe hepatic impairment.
7. Contraindications, Precautions & High-Risk Warnings
- Hypersensitivity to any constituent active ingredient or excipient; severe organ impairment contraindicated for individual components.
Key Clinical Precautions: Verify individual constituent ceilings and renal/hepatic dose adjustments when prescribing fixed-dose combinations.
8. Adverse Effects Profile
- Component-related gastrointestinal, metabolic, or hemodynamic effects; refer to constituent monographs.
- Severe hypersensitivity, organ toxicity, or electrolyte/metabolic derangement.
9. Major Drug–Drug, Drug–Food & Drug–Herb Interactions
- Check drug-drug interactions for all constituent active ingredients.
10. Clinical Monitoring, Patient Counselling & Storage
Clinical & Laboratory Monitoring: Monitor clinical efficacy, blood pressure/glycaemic/microbiological markers, and baseline organ function.
Pharmacist Patient Counselling Points:
- Explain dosing schedule, adherence, food timing, and warning signs for each active component.
Storage, Stability & Dispensing Safeguards: Store below 30°C protected from moisture and light. Verify exact strength ratio before dispensing.
11. Visual Pharmacology & Mechanism Diagram (svg-v339-01-adme-12-step-journey)
12. Authoritative References, Regulatory Sources & Editorial Disclaimer
Primary Compendial & Guideline Reference: Indian Pharmacopoeia (IP 2022) • National List of Essential Medicines (NLEM 2022) • CDSCO Approved FDC List
Official Verification Portals: Indian Pharmacopoeia Commission (IPC) & National Formulary of India (NFI) • Central Drugs Standard Control Organization (CDSCO) • Ministry of Health & Family Welfare — NLEM 2022 • NCBI Bookshelf / StatPearls Pharmacology Reference • DailyMed (US FDA Official Prescribing Reference)
Last Medically & Pharmaceutically Reviewed: 2026-11-10 • Verification Status: VERIFIED_EDUCATIONAL_CONTENT
Educational & Clinical Disclaimer: This reference profile is published solely for pharmacy education, academic study, and professional clinical reference. It does not substitute for patient-specific clinical judgement, qualified specialist oncology/medical supervision, or official CDSCO/IP prescribing information. Never self-medicate with prescription, Schedule H/H1/X, NDPS, or oncology medicines.
13. Related Reference Monographs, Educational Guides & Visual Concept
💊 Related Pharmacological / Category Profiles
- [3.2] Telmisartan — Angiotensin II Receptor Blocker (ARB) with Partial PPAR-gamma Ago
- [3.3] Losartan Potassium — Angiotensin II Receptor Blocker (ARB; selective AT1 antagonist)
- [3.4] Olmesartan Medoxomil — Angiotensin II Receptor Blocker (ARB) (Ester Prodrug)
- [3.1] Amlodipine (as Amlodipine Besylate) — Dihydropyridine Calcium Channel Blocker (CCB); Arterial Vasodilat